TABLE 2

L-AMB adverse effects and risk factors

VariableValue for patients who:P value
Did not meet RIFLE criteria (n = 63)Met RIFLE criteria (n = 40)
L-AMB dose administered [no. (%)]
    3 mg/kg/day55 (87.3)32 (80.0)0.40
    5 mg/kg/day3 (4.8)1 (2.5)0.99
    5 mg/kg/day to 3 mg/kg/day3 (4.8)1 (2.5)0.99
    Days of L-AMB [median (IQR)]8 (4–16)13 (9–18)0.009
Infusion reaction [no. (%)]
    None59 (93.7)38 (95.0)0.99
    Cough1 (1.6)0 (0)1.00
    Cough plus dyspnea1 (1.6)0 (0)1.00
    Cough, vomiting, dyspnea1 (1.6)0 (0)1.00
    Rash0 (0.0)1 (2.5)0.39
    Back pain1 (1.6)1 (2.5)0.99
SeCr (mg/dl) [median (IQR)]
    Baseline0.59 (0.46–0.74)0.46 (0.40–0.61)0.32
    Highest0.64 (0.53–0.85)1.17 (0.72–1.41)<0.0001
    End of therapy0.68 (0.48–0.99)0.97 (0.26–1.41)0.32
    Wk after completion0.70 (0.51–1.11)1.1 (0.82–1.32)0.40
Serum potassium (meq/liter) [median (IQR)]
    Baseline4.0 (3.6–4.2)3.9 (3.7–4.3)0.74
    Lowest3.5 (3.1–4.2)3.1 (2.8–3.3)0.07
    End of therapy3.7 (3.4–4.5)3.8 (3.3–4.2)0.98
    Wk after completion3.8 (3.4–4.1)4.2 (3.7–4.5)0.04
Mean urine output [ml/kg · hr (±SD)]
    Baseline0.02 (±0.15)0.03 (±0.16)0.21
    Highest0.10 (±0.30)0.40 (±0.59)<0.0001
    End of therapy0.02 (±0.15)0.09 (±0.38)0.08
    Wk after completion0.02 (±0.15)0.04 (±0.19)0.75